Meibomian Gland Damaging By Glaucoma Treatments

Meibomian Gland Damaging By Glaucoma Treatments Overview Glaucoma is one of the leading causes of blindness worldwide, with a strong link to elevated intraocular pressure (IOP). Effective management of glaucoma primarily involves lowering IOP, usually through the use of topical eye drops. The health of the meibomian glands is crucial for maintaining

Open-Angle Glaucoma And Glaucoma Filtration Surgery

Open-Angle Glaucoma And Glaucoma Filtration Surgery Overview This population-based historic cohort study, spanning from 1997 to 2017, aimed to investigate the rate and risk factors associated with glaucoma filtration surgery (GFS) in individuals newly diagnosed with open-angle glaucoma (OAG) aged 45 and above. The cohort comprised 9420 patients diagnosed with OAG between

Retinal Nerve Fiber Wedge Defects In Glaucoma And Heart Disease

Retinal Nerve Fiber Wedge Defects In Glaucoma And Heart Disease The Study The study aimed to investigate the connection between localized vascular and retinal nerve fiber layer (RNFL) loss and an individual's genetic predisposition to both glaucoma and cardiovascular disease. Researchers used a statistical tool called polygenic risk scores (PRS) to assess

Ocular Surgery In Infants And Post-Op Eye Drop Risks

Ocular Surgery In Infants And Post-Op Eye Drop Risks Overview This clinical observational cohort study delves into the prevalence and risk factors associated with hypothalamus-pituitary-adrenal (HPA) axis suppression in infants subjected to glucocorticoid (GC) eye drops subsequent to ocular surgery, focusing on cataract and glaucoma procedures. The research aims to discern the

Cholesterol Screening To Aid In Glaucoma Detection

Cholesterol Screening To Aid In Glaucoma Detection Overview Although intraocular pressure is the primary risk factor for glaucoma, additional risk factors should also be considered. This systematic review and meta-analysis summarize the evidence of the association between cholesterol parameters (total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels) and glaucoma and

Ovarian adenocarcinoma with glaucoma: A case report

Ovarian adenocarcinoma with glaucoma: A case report Introduction Metastatic tumor accounts for the most common ocular malignancy in adults. In rare cases, ocular metastasis can represent the initial manifestation of an undiagnosed primary cancer such as breast and lung cancers. Patients usually present with visual field defects, ocular pain, floaters, photophobia, or

How to Control Eye Pressure in Glaucoma

Patient Education This article is tailored for patients. Refer your patients to this article for them to learn more about their condition. How to Control Eye Pressure in Glaucoma The irreversible damage of glaucoma is one of the leading causes of blindness among people ages 60 years and above(1). This condition is

Optic 3D Modeling in Ophthalmic Treatment

Optic 3D Modeling in Ophthalmic Treatment Visual impairment is a global health concern. Visually impaired patients are at high risk for accidents, depression, and social withdrawal. Eye disorders like age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and retinitis pigmentosa (RP) cause irreparable vision loss and affect the quality of life of

iStent Combination Therapy for Glaucoma and Cataracts

iStent Combination Therapy for Glaucoma and Cataracts Considering that glaucoma is the most common cause of irreversible vision loss and the third most common cause of vision loss worldwide, with cataracts and refractive error being the most prevalent causes, iStent combination therapy to treat glaucoma and cataracts has high therapeutic value. 

Combination IOP Reduction Therapy in Open-Angle Glaucoma

Combination IOP Reduction Therapy in Open-Angle Glaucoma GLAUCOMA BACKGROUND Globally, glaucoma is a leading cause of permanent blindness. As of 2020, about 80 million people worldwide, and 3 million Americans, are affected by glaucoma. The most common form of glaucoma is open-angle glaucoma. Unfortunately, the primary risk factor for open-angle glaucoma is

Meibomian Gland Damaging By Glaucoma Treatments